

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on January 31, 2007.

PATENT
Attorney Docket No.: 020460-000930US
Client Ref. No.: 143.09

TOWNSEND and TOWNSEND and CREW LLP

By: 

JoAnn Evangelista

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SIRHAN, MOTASIM et al.

Application No.: 09/783,254

Filed: February 13, 2001

For: INTRAVASCULAR DELIVERY
OF MIZORIBINE

Customer No.: 60168

Confirmation No. 1701

Examiner: Miller, Cheryl

Technology Center/Art Unit: 3738

**WRITTEN CONFIRMATION OF
TELEPHONE CONFERENCE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants gratefully acknowledge the courteous and helpful telephone interview with Examiner Miller on January 24, 2007. D. Bommi Bommannan and Kunihiro Ito, as representatives of the Assignee, and the undersigned attorney of record, participated in the call with Examiner Miller.

During the telephone conference, it was agreed that the discussion of drug dosages on page 2 of the Office Action mailed November 30, 2006, should be corrected in two ways. First, the amount of mycophenolic acid disclosed in the Gregory '257 patent is based on the weight (kilogram) of the patient, not of the implant carrier. Furthermore, it was agreed that no discussion of mizoribine concentration or dosages is discussed anywhere in the Gregory '257 patent.


PATENT

Attorney Docket No.: 020460-000930US

Client Ref. No.: 143.09

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,


James M. Heslin
Reg. No. 29,541

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 415-576-0300
JMH:jke
60970373 v1